NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA

Insider buying of $629,000, strong Phase 2a NEO100 data and new financing together frame a pivotal period for NeOnc.

Rhea-AI Summary

NeOnc Technologies Holdings (NTHI) reported substantial insider buying following positive Phase 2a data for its brain cancer candidate NEO100.

Since announcing Phase 2a results on August 12, two senior executives have bought approximately $629,000 of stock in open‑market transactions using personal funds, totaling 160,016 shares combined. CEO Amir F. Heshmatpour’s post‑results purchases reached 111,000 shares for about $418,700, including 35,000 shares on September 15 for roughly $115,400 at a weighted average price near $3.30. Founder and CMO/CSO Thomas C. Chen acquired 49,016 shares for about $210,000.

The NEO100‑01 Phase 2a study met its primary endpoint with six‑month progression‑free survival of 48.9% versus a 20% benchmark, a reported p‑value of 0.0047, and median overall survival of 26.09 months. NeOnc also completed Phase 1 dose escalation for its second program, NEO212, and recently closed a $15 million registered direct offering to support ongoing clinical work.

Positive

• Executives bought 160,016 shares for approximately $629,000 in open-market, personal-fund purchases since August 12
• CEO post-results buying totals 111,000 shares for about $418,700, including 35,000 shares at roughly $3.30
• Phase 2a NEO100 trial met primary endpoint: 6-month PFS 48.9% vs 20% benchmark, p=0.0047
• Median overall survival in NEO100-01 reported at 26.09 months
• NEO212 program completed Phase 1 dose escalation and set a recommended Phase 2 dose
• $15 million registered direct offering adds capital to advance the clinical pipeline

Negative

• A $15 million registered direct offering implies issuance of new shares and potential dilution for existing shareholders

Key Figures

Combined insider purchases: $629,000 Shares purchased: 160,016 shares Heshmatpour purchase: 35,000 shares +5 more

Combined insider purchases

$629,000

Open-market purchases since the August 12 Phase 2a results

Shares purchased

160,016 shares

Combined purchases by two senior executives

Heshmatpour purchase

35,000 shares

September 15 open-market purchase

Heshmatpour purchase value

$115,400

September 15 purchase at a weighted average price of $3.30

Six-month progression-free survival

48.9%

NEO100-01 Phase 2a study

Standard-of-care benchmark

20%

Pre-specified benchmark for six-month progression-free survival

P-value

0.0047

NEO100-01 Phase 2a study

Median overall survival

26.09 months

NEO100-01 Phase 2a study

Historical Context

4 past events · Latest: Sep 15

4 events

1. Sep 15

   Insider buying

   24h Move

   -12.4%

   CEO purchased additional shares after the company announced institutional financing

2. Sep 14

   Insider buying

   24h Move

   +2.7%

   CEO purchase accompanied progress toward the next regulatory step for NEO100

3. Sep 09

   Registered offering

   24h Move

   -11.1%

   Company priced a registered direct offering to fund clinical programs

4. Sep 08

   Phase 2a data

   24h Move

   -19.1%

   NEO100 reported positive progression-free survival and overall survival results

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 2a, progression-free survival, p-value, primary endpoint, +1 more

5 terms

phase 2a medical

"following positive Phase 2a results for its experimental brain-cancer therapy"

Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.

progression-free survival medical

"six-month progression-free survival of 48.9%"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

p-value medical

"The company reported a p-value of 0.0047"

A p-value is a number that helps determine how likely it is that a result or pattern happened by chance rather than because of a real effect. For investors, a low p-value suggests that the findings in a study or analysis are probably meaningful and not just random noise—like noticing a pattern in coin flips that’s unlikely to occur by chance. This helps in assessing the reliability of information used to make financial decisions.

primary endpoint medical

"the NEO100-01 Phase 2a study met its primary endpoint"

The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.

registered direct offering financial

"announced a $15 million registered direct offering"

A registered direct offering is a way for a company to sell new shares of its stock directly to select investors with regulatory approval. This method allows the company to raise funds quickly and efficiently without needing a public auction, similar to offering exclusive access to a limited number of buyers. For investors, it often provides an opportunity to purchase shares at a favorable price, while giving the company immediate access to capital.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DENVER, Sept. 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- NeOnc Technologies Holdings (NASDAQ: NTHI) executives put even more personal capital behind the company, following positive Phase 2a results for its experimental brain-cancer therapy NEO100.

The latest purchase brings the total open-market buying by two senior executives to approximately $629,000 since the company announced its Phase 2a results on August 12.

CEO, President and Executive Chairman Amir F. Heshmatpour purchased another 35,000 shares on September 15 for approximately $115,400, at a weighted average price of roughly $3.30 per share. That pushes his post-results purchases to 111,000 shares for approximately $418,700, at an average cost of about $3.77 per share.

Founder, Chief Medical Officer and Chief Scientific Officer Thomas C. Chen, MD, PhD, purchased another 49,016 shares for approximately $210,000. Combined, the two executives have now purchased 160,016 shares for approximately $629,000, according to the company, and all of the purchases were made in the open market with personal funds.

Heshmatpour said the buying reflects his conviction following the clinical results, “The strength of our Phase 2a results reinforces my conviction in NeOnc's mission and the potential of our NEO platform,” he said. Heshmatpour added that his latest purchases bring his personal investment in NeOnc shares to more than $1.5 million over the past year.

The insider buying comes against the backdrop of a potentially important clinical milestone, as NeOnc reported that its NEO100-01 Phase 2a study met its primary endpoint, with six-month progression-free survival of 48.9%, compared with a pre-specified 20% benchmark for standard of care. The company reported a p-value of 0.0047 and median overall survival of 26.09 months.

NEO100 is being developed for central nervous system cancers, an area where treatment remains particularly challenging because of the blood-brain barrier. NeOnc's platform is designed around drug candidates and delivery approaches intended to address that barrier.

The company is not putting all of its clinical ambitions behind a single candidate. Its second program, NEO212, has completed Phase 1 dose escalation and established a recommended Phase 2 dose, giving NeOnc another potential development catalyst.

Meanwhile, the company recently announced a $15 million registered direct offering, providing additional capital as it advances its clinical programs.

That combination, positive Phase 2a data, substantial open-market insider purchases, fresh financing and another clinical program moving toward Phase 2, has put NTHI at an important inflection point and the message from management is unmistakable: executives are continuing to commit their own money to the company after the NEO100 readout.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

About 24/7 Market News

In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much stock did NeOnc’s CEO Amir F. Heshmatpour buy after the Phase 2a results?

Amir F. Heshmatpour purchased a total of 111,000 shares after the Phase 2a readout, for approximately $418,700. This includes 35,000 shares bought on September 15 for about $115,400 at a weighted average price of roughly $3.30 per share. He said these transactions contribute to more than $1.5 million of his personal investment in NeOnc shares over the past year.

What insider buying did Thomas C. Chen report?

Founder, Chief Medical Officer and Chief Scientific Officer Thomas C. Chen purchased 49,016 shares of NeOnc for approximately $210,000. The company states that all of his purchases, like those of the CEO, were made in the open market using personal funds.

What benchmark did the NEO100 Phase 2a study use for its primary endpoint?

The NEO100-01 Phase 2a study used a pre-specified 20% six-month progression-free survival benchmark for standard of care as its comparator. The study reported that NEO100 achieved 48.9% six-month progression-free survival against this benchmark.

What is the development status of NeOnc’s second program, NEO212?

NeOnc reports that NEO212 has completed Phase 1 dose escalation and that a recommended Phase 2 dose has been established. The company presents this as providing another potential development catalyst in addition to NEO100.

How does NeOnc describe the focus of its drug platform?

NeOnc describes its platform as being built around drug candidates and delivery approaches designed to address the blood-brain barrier, targeting central nervous system cancers where treatment remains challenging because many therapies cannot effectively cross this barrier.

What purpose does the $15 million registered direct offering serve for NeOnc?

The company states that the recently announced $15 million registered direct offering provides additional capital as it advances its clinical programs, including NEO100 and NEO212.